PARKINSON DISEASE, LATE-ONSET
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report on a proof-of-principle study for using an ultra-sensitive and specific, real-time quaking-induced conversion assay to detect pathological α-synuclein in the submandibular gland tissues of PD patients.
|
31758740 |
2020 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evolving concepts on Parkinson's disease (PD) pathology suggest that α-synuclein (aSYN) promote dopaminergic neuron dysfunction and death through accumulating in the mitochondria.
|
31727879 |
2019 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
Biomarker
|
disease |
BEFREE |
CSF α-synuclein inversely correlates with non-motor symptoms in a cohort of PD patients.
|
30348495 |
2019 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies revealed that CSF α-synuclein levels are higher in Parkinson's disease (PD) patients with RBD compared to those without RBD, even if α-synuclein does not seem to predict conversion of iRBD into PD.
|
30637520 |
2019 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
Biomarker
|
disease |
BEFREE |
α-Synuclein (αSyn) forms amyloid fibrils in the neurons of Parkinson's disease (PD) patients'.
|
31697492 |
2019 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
Biomarker
|
disease |
BEFREE |
α-Synuclein (α-Syn) forms pathological amyloid aggregates deposited in Lewy bodies and Lewy neurites in the brain of Parkinson's disease (PD) patients.
|
31749672 |
2019 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Single-nucleotide polymorphisms (SNPs) in the SNCA gene encoding alpha-synuclein have been shown to affect the PD phenotype.
|
31102707 |
2019 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
Biomarker
|
disease |
BEFREE |
The progressive accumulation, aggregation, and spread of α-synuclein (αSN) are common hallmarks of Parkinson's disease (PD) pathology.
|
31270237 |
2019 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies in Parkinson's disease (PD) patients and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys have shown that abnormal α-synuclein is accumulated in the olfactory glomeruli, suggesting that the lesions of PD are not only confined to the substantia nigra (SN) but also located in the olfactory bulb.
|
30728466 |
2019 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
Biomarker
|
disease |
BEFREE |
The protein α-synuclein, a major component of Lewy bodies in nigral neurons of aged and Parkinson's disease (PD) patients, normally co-localizes with synaptophysin and regulates the pool of synaptic vesicles.
|
30738909 |
2019 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
Biomarker
|
disease |
BEFREE |
Emerging findings suggest that Parkinson's disease (PD) pathology (α-synuclein accumulation) and neuronal dysfunction may occur first in peripheral neurons of the autonomic nervous system including the enteric branches of the vagus nerve.
|
31079293 |
2019 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, while rare SNCA gene mutations are causal for a minority of familial PD patients, in sporadic PD (where common SNCA polymorphisms are the most consistent genetic risk factor across populations worldwide, accounting for 95% of PD patients) α-syn pathology is an important feature.
|
31240402 |
2019 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
Biomarker
|
disease |
BEFREE |
α-Synuclein, a protein implicated in Parkinson's disease, is found in aggregated form within Lewy bodies that are characteristically observed in the brains of PD patients.
|
29702073 |
2018 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Global measures (but not local efficiency) and CSF α-synuclein were significantly lower in PD patients.
|
29436735 |
2018 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
Biomarker
|
disease |
BEFREE |
Over the last two decades, many experimental and clinical studies have provided solid evidence that alpha-synuclein (α-syn), a small, natively unfolded protein, is closely related to Parkinson's disease (PD) pathology.
|
29780350 |
2018 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
Biomarker
|
disease |
BEFREE |
The intrinsically disordered protein α-synuclein (aSN) forms insoluble aggregates in the brains of Parkinson's disease (PD) patients.
|
30067901 |
2018 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
Biomarker
|
disease |
BEFREE |
Parkinson's disease (PD) pathology is characterized by the abnormal accumulation and aggregation of the pre-synaptic protein α-synuclein in the dopaminergic neurons as Lewy bodies (LBs).
|
29027056 |
2018 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
Biomarker
|
disease |
BEFREE |
The α-synuclein protein exists in vivo in a variety of covalently modified and aggregated forms associated with Parkinson's disease (PD) pathology.
|
28117497 |
2017 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we investigated the miRNA profiles in A53T-α-synuclein transgenic mice and analyzed the candidate miRNAs in the cerebrospinal fluid (CSF) of PD patients.
|
27965467 |
2017 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
Biomarker
|
disease |
BEFREE |
The intrinsically disordered human protein alpha-Synuclein (αS) has a prominent role in Parkinson's disease (PD) pathology.
|
28298083 |
2017 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
Biomarker
|
disease |
BEFREE |
In Parkinson's disease (PD) patients, however, their vulnerability and the transmission of pathological α-Synuclein are possible drawbacks that may prevent PD-specific iPSCs (PDiPSCs) from being used in clinical settings.
|
28233934 |
2017 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutations in the transmembrane protein 230 (TMEM230) gene were recently identified in a large Canadian pedigree and 7 smaller Chinese families, nominating TMEM230 as the third gene causing a Mendelian form of late onset Parkinson's disease (PD) with typical Lewy-body pathology (after synuclein alpha (SNCA) and leucine rich repeat kinase 2 (LRRK2)).
|
28568905 |
2017 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
Biomarker
|
disease |
BEFREE |
Parkinson's disease (PD) patients progressively accumulate intracytoplasmic inclusions formed by misfolded α-synuclein known as Lewy bodies (LBs).
|
28522732 |
2017 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lewy bodies and neurites, the pathological hallmarks found in the brain of Parkinson's disease (PD) patients, are primarily composed of aggregated and hyperphosphorylated alpha-synuclein.
|
28126589 |
2017 |
PARKINSON DISEASE, LATE-ONSET
|
0.100 |
Biomarker
|
disease |
BEFREE |
α-Synuclein plays important roles in the development of Parkinson's disease (PD) pathologies.
|
27546826 |
2016 |